Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Adult sickle cell drug proves effective in young children

20.09.2005


A drug used for the treatment of sickle cell anemia in adults has now been shown to cause significant improvements in very young children with the disorder. The finding is an important one as these young patients are especially vulnerable to serious organ failure and even death at an early age. The study results will be published in the October 1, 2005, issue of Blood, the official journal of the American Society of Hematology.



Sickle cell anemia is a genetic blood disorder that can cause severe pain, fatigue, and organ damage to the kidneys, spleen, and liver. It occurs in about one in every 500 African-Americans. In the new study, 21 children from two to four years old who had sickle cell anemia were given the drug hydroxyurea orally as a flavored liquid formula. A majority of the children took the drug for at least four years and more than half of the participants completed all six years of the study.

The treatment was well-tolerated in the patients, with only one child’s dosage permanently reduced during the study due to adverse effects. The drug’s primary function, to counteract the effects of the disease by increasing and sustaining fetal hemoglobin production, was achieved in all study participants. Patients treated with hydroxyurea also weighed more and were taller than untreated children with the disorder – their growth rates were even comparable to those of normal children.


Another measure of success of the therapy was that the study patients had improved spleen function, an important finding as many children with sickle cell anemia lose spleen function by two years of age. Participants also experienced significantly fewer incidents of acute chest syndrome, a potentially life-threatening disorder associated with sickle cell disease. During the study, one four-year-old girl died of sepsis, a toxic bacterial infection, though no increased risk of sepsis was found among the hydroxyurea-treated patients.

"This study demonstrates that hydroxyurea is an efficient and safe treatment option for young children with sickle cell anemia," said Jane Hankins, M.D., M.S., of St. Jude Comprehensive Sickle Cell Center and lead study author. "As sickle cell anemia is a chronic disorder, having a drug that can be started early and continued long-term with few adverse effects is of significant importance to the way we treat this debilitating disease."

Laura Stark | EurekAlert!
Further information:
http://www.hematology.org
http://www.bloodjournal.org

More articles from Life Sciences:

nachricht No gene is an island
25.07.2017 | Institute of Science and Technology Austria

nachricht Topologische Quantenchemie
21.07.2017 | Max-Planck-Institut für Chemische Physik fester Stoffe

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: 3-D scanning with water

3-D shape acquisition using water displacement as the shape sensor for the reconstruction of complex objects

A global team of computer scientists and engineers have developed an innovative technique that more completely reconstructs challenging 3D objects. An ancient...

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

Ultrathin device harvests electricity from human motion

24.07.2017 | Power and Electrical Engineering

Scientists announce the quest for high-index materials

24.07.2017 | Materials Sciences

ADIR Project: Lasers Recover Valuable Materials

24.07.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>